9. Colossal valuations.
We’ve been seeing industrial biotech reaching orbital velocity amongst public companies. Twist, Beyond Meat, REG, Amyris, Aemetis and Gevo to name just a few that have been on a share tear in recent months, though valuations have receded since Februarys’ highs. This slide gobsmacked us, confirming that interest is soaring for privately held companies. Pivot Bio, valued at 1.6B, Inscripta, at 1.35B, Provivi’s double what’s been invested, so’s Evolve and Crop Enhancement, and GreenLight’s added a lot of value too.

Use your ← → (arrow) keys to browse